BR0113148A - Composições de 2-piridinamina e métodos relacionados - Google Patents
Composições de 2-piridinamina e métodos relacionadosInfo
- Publication number
- BR0113148A BR0113148A BR0113148-6A BR0113148A BR0113148A BR 0113148 A BR0113148 A BR 0113148A BR 0113148 A BR0113148 A BR 0113148A BR 0113148 A BR0113148 A BR 0113148A
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- pyridinamine
- related methods
- cell death
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"COMPOSIçõES DE 2-PIRIDINAMINA E MéTODOS RELACIONADOS". A presente invenção refere-se a composições farmacêuticas neuroprotetoras compreendendo 2-piridinaminas. Esta invenção também fornece métodos de uso destas composições para prevenir morte de célula isquêmica, particularmente morte de célula neuronal, e reduz a probabilidade de morte de célula neuronal em um indivíduo devido a um evento traumático. Finalmente, esta invenção fornece um mecanismo para administrar a um indivíduo as presentes composições farmacêuticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22379500P | 2000-08-08 | 2000-08-08 | |
PCT/US2001/041565 WO2002011724A2 (en) | 2000-08-08 | 2001-08-06 | Neuroprotective 2-pyridinamine compositions and related methods |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0113148A true BR0113148A (pt) | 2003-07-08 |
Family
ID=22837998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0113148-6A BR0113148A (pt) | 2000-08-08 | 2001-08-06 | Composições de 2-piridinamina e métodos relacionados |
Country Status (13)
Country | Link |
---|---|
US (2) | US20020198219A1 (pt) |
EP (1) | EP1317266A2 (pt) |
JP (1) | JP2004510707A (pt) |
CN (1) | CN1635890A (pt) |
AR (1) | AR030140A1 (pt) |
AU (1) | AU2001278206A1 (pt) |
BR (1) | BR0113148A (pt) |
CA (1) | CA2418912A1 (pt) |
IL (1) | IL154267A0 (pt) |
MX (1) | MXPA03001227A (pt) |
NZ (1) | NZ524101A (pt) |
WO (1) | WO2002011724A2 (pt) |
ZA (1) | ZA200301861B (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6811992B1 (en) | 1998-05-14 | 2004-11-02 | Ya Fang Liu | Method for identifying MLK inhibitors for the treatment of neurological conditions |
EP1363702A4 (en) * | 2001-01-30 | 2007-08-22 | Cytopia Pty Ltd | PROCESS FOR INHIBITING KINASES |
EP1689715B1 (en) | 2003-12-03 | 2011-02-09 | YM BioSciences Australia Pty Ltd | Tubulin inhibitors |
PL2402319T3 (pl) | 2006-03-31 | 2018-02-28 | Novartis Ag | Inhibitory DGAT |
GB0606774D0 (en) * | 2006-04-03 | 2006-05-10 | Novartis Ag | Organic compounds |
CA2682676A1 (en) * | 2007-04-19 | 2008-10-30 | Novartis Ag | Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5 |
GB0821307D0 (en) * | 2008-11-21 | 2008-12-31 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
WO2013081094A1 (ja) * | 2011-11-30 | 2013-06-06 | 東レ株式会社 | イミダゾ[1,2-a]ピリジン誘導体及びその医薬用途 |
WO2014121055A2 (en) | 2013-02-04 | 2014-08-07 | Janssen Pharmaceutica Nv | Flap modulators |
TWI644899B (zh) | 2013-02-04 | 2018-12-21 | 健生藥品公司 | Flap調節劑 |
AU2018243691B2 (en) * | 2017-03-27 | 2022-05-12 | Cardurion Pharmaceuticals, Llc | Heterocyclic compound |
GB201809102D0 (en) * | 2018-06-04 | 2018-07-18 | Univ Oxford Innovation Ltd | Compounds |
JP7447098B2 (ja) | 2018-09-25 | 2024-03-11 | カーデュリオン・ファーマシューティカルズ・インコーポレイテッド | アミノピリミジン化合物 |
US11795172B2 (en) | 2020-09-28 | 2023-10-24 | Cardurion Pharmaceuticals, Inc. | Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors |
WO2023283488A2 (en) * | 2021-07-09 | 2023-01-12 | Chan Zuckerberg Biohub, Inc. | Cdk19-selective inhibitors, and methods of use thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0000816A1 (en) * | 1977-08-06 | 1979-02-21 | Beecham Group Plc | Substituted amino-pyridine derivatives, processes for their preparation and pharmaceutical compositions containing them |
US5506231A (en) * | 1989-03-31 | 1996-04-09 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
US5519035A (en) * | 1993-07-02 | 1996-05-21 | Cornell Research Foundation, Inc. | Treatment of stroke or in anticipation of the occurrence of brain ischemia |
US5536718A (en) * | 1995-01-17 | 1996-07-16 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
KR0138353Y1 (ko) * | 1996-12-13 | 1999-04-01 | 주식회사부윤테크 | 일회용 주사기 |
WO1998028257A1 (fr) * | 1996-12-24 | 1998-07-02 | Chugai Seiyaku Kabushiki Kaisha | Derives d'amine aromatiques ayant une action inhibitrice a l'egard des nos |
US6200993B1 (en) * | 1999-05-05 | 2001-03-13 | Merck Frosst Canada & Co. | Heterosubstituted pyridine derivatives as PDE4 inhibitors |
US6316474B1 (en) * | 1999-10-29 | 2001-11-13 | Merck & Co., Inc. | 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists |
ATE293962T1 (de) * | 2000-02-25 | 2005-05-15 | Hoffmann La Roche | Adenosin-rezeptor modulatoren |
-
2001
- 2001-08-06 JP JP2002517060A patent/JP2004510707A/ja active Pending
- 2001-08-06 WO PCT/US2001/041565 patent/WO2002011724A2/en not_active Application Discontinuation
- 2001-08-06 US US09/922,658 patent/US20020198219A1/en not_active Abandoned
- 2001-08-06 NZ NZ524101A patent/NZ524101A/en not_active Application Discontinuation
- 2001-08-06 BR BR0113148-6A patent/BR0113148A/pt not_active IP Right Cessation
- 2001-08-06 MX MXPA03001227A patent/MXPA03001227A/es unknown
- 2001-08-06 EP EP01956179A patent/EP1317266A2/en not_active Withdrawn
- 2001-08-06 CN CNA018166911A patent/CN1635890A/zh active Pending
- 2001-08-06 IL IL15426701A patent/IL154267A0/xx unknown
- 2001-08-06 CA CA002418912A patent/CA2418912A1/en not_active Abandoned
- 2001-08-06 AU AU2001278206A patent/AU2001278206A1/en not_active Abandoned
- 2001-08-08 AR ARP010103804A patent/AR030140A1/es unknown
-
2003
- 2003-03-06 ZA ZA200301861A patent/ZA200301861B/en unknown
- 2003-03-28 US US10/402,094 patent/US20030225085A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2001278206A1 (en) | 2002-02-18 |
US20020198219A1 (en) | 2002-12-26 |
NZ524101A (en) | 2004-11-26 |
US20030225085A1 (en) | 2003-12-04 |
CA2418912A1 (en) | 2002-02-14 |
WO2002011724A3 (en) | 2002-08-15 |
CN1635890A (zh) | 2005-07-06 |
JP2004510707A (ja) | 2004-04-08 |
EP1317266A2 (en) | 2003-06-11 |
MXPA03001227A (es) | 2004-09-10 |
AR030140A1 (es) | 2003-08-13 |
ZA200301861B (en) | 2004-07-07 |
IL154267A0 (en) | 2003-09-17 |
WO2002011724A2 (en) | 2002-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0113148A (pt) | Composições de 2-piridinamina e métodos relacionados | |
BR0308429A (pt) | Aroilpiridinonas monocìclicas como agentes antiinflamatórios | |
GT199900203A (es) | Composiciones de celecoxib. | |
HN2002000275A (es) | Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados | |
MXPA03003511A (es) | Composicion topica que contiene al menos una vitamina d o un analogo de vitamina de y al menos un corticosteroide. | |
BR0107869A (pt) | Composições farmacêuticas eletrogiradas | |
BR0210056A (pt) | composições e métodos para tratamento de hiperplasia | |
BR0212052A (pt) | Preparação de composição farmacêutica de liberação prolongada | |
BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
SG152257A1 (en) | Topical preparation containing ambroxol | |
CO5720000A2 (es) | Derivados de macrolidos con actividad antiinflamatoria, su procedimiento de sintesis y composiciones farmaceuticas que los contienen | |
BR9909138A (pt) | Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda | |
AU9018898A (en) | Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments | |
BR0113165A (pt) | Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados | |
BR0211198A (pt) | Composições farmacêuticas e seu uso | |
DE60103512D1 (de) | Pharmazeutische zusammensetzung enthaltend pemetrexed zusammen mit monothioglycerol, l-cystein oder thioglykolsäure | |
ITMI20022292A1 (it) | 9a-azalidi ad attivita' antiinfiammatoria. | |
CL43546B (es) | Compuesto derivado de tetrahidroquinolina con actividad moduladora del receptor fsh; composicion farmaceutica que contiene al compuesto; y uso del compuesto en la preparacion de medicamentos para la regulacion de la fertilidad. | |
BR0008829A (pt) | Inibição sinérgica de replicação viral porhidrocarbonetos de cadeia longa e análogos denucleosìdeos | |
BR9915215A (pt) | Composição farmacêutica para liberação modificada de sensibilizador de insulina | |
BR9915692A (pt) | Monohidrato de bromidrato de eletriptano | |
ATE410154T1 (de) | Pharmazeutische zusammensetzung enthaltend 2,4- dichlorbenzylalkohol und amylmetakresol | |
AR036321A1 (es) | Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia. | |
IT1283110B1 (it) | Composti a scheletro colchicinico,loro uso come farmaci e composizioni che li contengono | |
BR0317947A (pt) | Inibidores de quinurenina 3-hidroxilase para o tratamento de diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: JOHNSON AND JOHNSON (US) Free format text: TRANSFERIDO DE: ORTHO-MCNEIL PHARMACEUTICAL, INC. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A,6AE7A ANUIDADE |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008. |